Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neoplants SAS is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and 1 distinct art unit, reflecting a concentrated effort on a single patent matter. The technical review is localized within one specific division of the USPTO, suggesting that the company's current patent activity is focused on a specific set of claims.
MCWILLIAMS, KELSEY LYNN is the busiest examiner for the company, currently handling 1 pending office action. This figure accounts for the entirety of the company's active office actions. Because there is only 1 distinct examiner, the applicant's interaction with the patent office is limited to a single individual. This concentration can lead to a more consistent dialogue between the applicant and the USPTO regarding the technical merits of the application.
The presence of 1 pending office action suggests that the company is in a focused phase of its patent prosecution. The involvement of 1 distinct art unit ensures that the technical merits of the application are being judged by one specialized team. To advance the portfolio, the applicant must successfully resolve the 1 pending office action with MCWILLIAMS, KELSEY LYNN. This simplified structure allows for a highly targeted approach to resolving the outstanding issues in the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCWILLIAMS, KELSEY LYNN | 1 | 89.2% | +5.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284959 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | MCWILLIAMS, KELSEY LYNN | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284959 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | MCWILLIAMS, KELSEY LYNN | 1663 | §103§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeoplants SAS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kelsey Lynn Mcwilliams has the most, with 1 of Neoplants SAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
